NOD2, CD14 and TLR4 mutations do not influence response to adalimumab in patients with Crohn's disease: a preliminary report Las mutaciones de NOD2, CD14 y TLR4 no influyen sobre la respuesta al adalimumab en pacientes con enfermedad de Crohn: informe preliminar
Introduction: adalimumab is a recombinant fully-human monoclonal immunoglobulin (IgG1) antibody utilized in the treatment of Crohn's disease. Unfortunately no clinical or genetic markers exist to predict response to anti-tumor necrosis factor-alpha (TNF) therapy. The aim of this study was to ev...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Aran Ediciones
2010-10-01
|
| Series: | Revista Espanola de Enfermedades Digestivas |
| Subjects: | |
| Online Access: | http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082010001000005 |
| _version_ | 1818528468501004288 |
|---|---|
| author | M. Barreiro-de Acosta S. Ouburg S. A. Morré J. B. A. Crusius A. Lorenzo J. Potel A. S. Peña J. E. Domínguez-Muñoz |
| author_facet | M. Barreiro-de Acosta S. Ouburg S. A. Morré J. B. A. Crusius A. Lorenzo J. Potel A. S. Peña J. E. Domínguez-Muñoz |
| author_sort | M. Barreiro-de Acosta |
| collection | DOAJ |
| description | Introduction: adalimumab is a recombinant fully-human monoclonal immunoglobulin (IgG1) antibody utilized in the treatment of Crohn's disease. Unfortunately no clinical or genetic markers exist to predict response to anti-tumor necrosis factor-alpha (TNF) therapy. The aim of this study was to evaluate the association between selected genes involved in cytokine regulation and response to adalimumab treatment in Crohn's disease. Methods: twenty-four patients with Crohn's disease either naïve (n = 8) or had lost response or were unable to tolerate the chimeric anti-TNF antibody infliximab (n=16) were enrolled in the study. Patients were genotyped for main polymorphisms in NOD2, CD14 and TLR4 genes. Response to adalimumab treatment was defined as a decrease of Crohn's disease activity index of at least 100 points or a closure of at least 50% of fistulas in case of fistulizing Crohn's disease. Results: overall, 75% of patients did respond to treatment. However, no statistically significant association was found between any of the genotypes and the response to adalimumab. Conclusions: in our small study group no association between the studied polymorphisms and response to adalimumab was apparent. Systematic studies to search for genetic markers of response to anti-TNF therapy are necessary. |
| first_indexed | 2024-12-11T06:50:10Z |
| format | Article |
| id | doaj.art-cff43b96e8164e9fbbf5862185cbdf67 |
| institution | Directory Open Access Journal |
| issn | 1130-0108 |
| language | English |
| last_indexed | 2024-12-11T06:50:10Z |
| publishDate | 2010-10-01 |
| publisher | Aran Ediciones |
| record_format | Article |
| series | Revista Espanola de Enfermedades Digestivas |
| spelling | doaj.art-cff43b96e8164e9fbbf5862185cbdf672022-12-22T01:16:56ZengAran EdicionesRevista Espanola de Enfermedades Digestivas1130-01082010-10-0110210591595NOD2, CD14 and TLR4 mutations do not influence response to adalimumab in patients with Crohn's disease: a preliminary report Las mutaciones de NOD2, CD14 y TLR4 no influyen sobre la respuesta al adalimumab en pacientes con enfermedad de Crohn: informe preliminarM. Barreiro-de AcostaS. OuburgS. A. MorréJ. B. A. CrusiusA. LorenzoJ. PotelA. S. PeñaJ. E. Domínguez-MuñozIntroduction: adalimumab is a recombinant fully-human monoclonal immunoglobulin (IgG1) antibody utilized in the treatment of Crohn's disease. Unfortunately no clinical or genetic markers exist to predict response to anti-tumor necrosis factor-alpha (TNF) therapy. The aim of this study was to evaluate the association between selected genes involved in cytokine regulation and response to adalimumab treatment in Crohn's disease. Methods: twenty-four patients with Crohn's disease either naïve (n = 8) or had lost response or were unable to tolerate the chimeric anti-TNF antibody infliximab (n=16) were enrolled in the study. Patients were genotyped for main polymorphisms in NOD2, CD14 and TLR4 genes. Response to adalimumab treatment was defined as a decrease of Crohn's disease activity index of at least 100 points or a closure of at least 50% of fistulas in case of fistulizing Crohn's disease. Results: overall, 75% of patients did respond to treatment. However, no statistically significant association was found between any of the genotypes and the response to adalimumab. Conclusions: in our small study group no association between the studied polymorphisms and response to adalimumab was apparent. Systematic studies to search for genetic markers of response to anti-TNF therapy are necessary.http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082010001000005Crohn's diseaseGenotypesAdalimumab |
| spellingShingle | M. Barreiro-de Acosta S. Ouburg S. A. Morré J. B. A. Crusius A. Lorenzo J. Potel A. S. Peña J. E. Domínguez-Muñoz NOD2, CD14 and TLR4 mutations do not influence response to adalimumab in patients with Crohn's disease: a preliminary report Las mutaciones de NOD2, CD14 y TLR4 no influyen sobre la respuesta al adalimumab en pacientes con enfermedad de Crohn: informe preliminar Revista Espanola de Enfermedades Digestivas Crohn's disease Genotypes Adalimumab |
| title | NOD2, CD14 and TLR4 mutations do not influence response to adalimumab in patients with Crohn's disease: a preliminary report Las mutaciones de NOD2, CD14 y TLR4 no influyen sobre la respuesta al adalimumab en pacientes con enfermedad de Crohn: informe preliminar |
| title_full | NOD2, CD14 and TLR4 mutations do not influence response to adalimumab in patients with Crohn's disease: a preliminary report Las mutaciones de NOD2, CD14 y TLR4 no influyen sobre la respuesta al adalimumab en pacientes con enfermedad de Crohn: informe preliminar |
| title_fullStr | NOD2, CD14 and TLR4 mutations do not influence response to adalimumab in patients with Crohn's disease: a preliminary report Las mutaciones de NOD2, CD14 y TLR4 no influyen sobre la respuesta al adalimumab en pacientes con enfermedad de Crohn: informe preliminar |
| title_full_unstemmed | NOD2, CD14 and TLR4 mutations do not influence response to adalimumab in patients with Crohn's disease: a preliminary report Las mutaciones de NOD2, CD14 y TLR4 no influyen sobre la respuesta al adalimumab en pacientes con enfermedad de Crohn: informe preliminar |
| title_short | NOD2, CD14 and TLR4 mutations do not influence response to adalimumab in patients with Crohn's disease: a preliminary report Las mutaciones de NOD2, CD14 y TLR4 no influyen sobre la respuesta al adalimumab en pacientes con enfermedad de Crohn: informe preliminar |
| title_sort | nod2 cd14 and tlr4 mutations do not influence response to adalimumab in patients with crohn s disease a preliminary report las mutaciones de nod2 cd14 y tlr4 no influyen sobre la respuesta al adalimumab en pacientes con enfermedad de crohn informe preliminar |
| topic | Crohn's disease Genotypes Adalimumab |
| url | http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082010001000005 |
| work_keys_str_mv | AT mbarreirodeacosta nod2cd14andtlr4mutationsdonotinfluenceresponsetoadalimumabinpatientswithcrohnsdiseaseapreliminaryreportlasmutacionesdenod2cd14ytlr4noinfluyensobrelarespuestaaladalimumabenpacientesconenfermedaddecrohninformepreliminar AT souburg nod2cd14andtlr4mutationsdonotinfluenceresponsetoadalimumabinpatientswithcrohnsdiseaseapreliminaryreportlasmutacionesdenod2cd14ytlr4noinfluyensobrelarespuestaaladalimumabenpacientesconenfermedaddecrohninformepreliminar AT samorre nod2cd14andtlr4mutationsdonotinfluenceresponsetoadalimumabinpatientswithcrohnsdiseaseapreliminaryreportlasmutacionesdenod2cd14ytlr4noinfluyensobrelarespuestaaladalimumabenpacientesconenfermedaddecrohninformepreliminar AT jbacrusius nod2cd14andtlr4mutationsdonotinfluenceresponsetoadalimumabinpatientswithcrohnsdiseaseapreliminaryreportlasmutacionesdenod2cd14ytlr4noinfluyensobrelarespuestaaladalimumabenpacientesconenfermedaddecrohninformepreliminar AT alorenzo nod2cd14andtlr4mutationsdonotinfluenceresponsetoadalimumabinpatientswithcrohnsdiseaseapreliminaryreportlasmutacionesdenod2cd14ytlr4noinfluyensobrelarespuestaaladalimumabenpacientesconenfermedaddecrohninformepreliminar AT jpotel nod2cd14andtlr4mutationsdonotinfluenceresponsetoadalimumabinpatientswithcrohnsdiseaseapreliminaryreportlasmutacionesdenod2cd14ytlr4noinfluyensobrelarespuestaaladalimumabenpacientesconenfermedaddecrohninformepreliminar AT aspena nod2cd14andtlr4mutationsdonotinfluenceresponsetoadalimumabinpatientswithcrohnsdiseaseapreliminaryreportlasmutacionesdenod2cd14ytlr4noinfluyensobrelarespuestaaladalimumabenpacientesconenfermedaddecrohninformepreliminar AT jedominguezmunoz nod2cd14andtlr4mutationsdonotinfluenceresponsetoadalimumabinpatientswithcrohnsdiseaseapreliminaryreportlasmutacionesdenod2cd14ytlr4noinfluyensobrelarespuestaaladalimumabenpacientesconenfermedaddecrohninformepreliminar |